Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Finasteride in Non-small Cell Lung Cancer
NCT02055170Phase 2Terminated
- Sponsor
- CancerCare Manitoba
- Start
- Jun 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of finasteride in non-small cell lung cancer (NSCLC), sponsored by CancerCare Manitoba. Primary endpoint: Change in proliferation at 6 weeks. Started Jun 2014; status: terminated.
02
Drugs
finasteride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02055170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055170.